Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 11/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 2/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17035584 | 1.00 | DNM1 (0.52) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL21091016 | 0.97 | DNM1 (0.57) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL13232029 | 0.97 | DNM1 (0.48) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL15188890 | 0.97 | DNM1 (0.48) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL25844944 | 0.95 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL25844886 | 0.95 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL21090668 | 0.95 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL6350676 | 0.95 | DNM1 (0.60) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL21698622 | 0.95 | DNM1 (0.52) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL5859562 | 0.95 | DNM1 (0.60) | DNM1MEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150239824-A1 | BRANCHED OR MACROCYCLIC POLYAMINES AND USES THEREOF | UNIVERSITE DE STRASBOURG (FR) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239824-A1 | BRANCHED OR MACROCYCLIC POLYAMINES AND USES THEREOF | SRM, SMS, PNMT | DNM1 512/4885MEN1 124/4885KMT2A 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.